The researchers identified 243 incidences of epilepsy, translating to incidences of 174.2 per 100,000 person-years among SGLT-2 inhibitor users and 231.5 per 100,000 among DPP-4 inhibitor users.

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Additionally, SGLT-2 inhibitors showed a trend toward reducing the risk for decompensated cirrhosis (HR, 0.74; 95% CI 0.54-1.00).

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

Doctors could soon be offering sodium-glucose cotransporter-2 (SGLT-2) inhibitors as a first line treatment option for all patients with diabetes, not just those with heart disease.1 The change has ...

After inverse probability of treatment weighting, the researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 ...

Compared with DPP-4 inhibitors, the risk of falls and hypoglycemia were lower in the SGLT-2 inhibitor group (HR, 0.82 [95% CI, 0.77-0.87] vs 0.75 [95% CI, 0.67-0.84], however the risk of syncope ...

Dementia rates per 100 person years were 0.22 for those using SGLT-2 inhibitors and 0.35 for those using DPP-4 inhibitors, corresponding to a 35% reduced risk of dementia associated with use of ...

BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 inhibitor to therapy for patients who have inadequate glycemic control, the ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ.

SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher risk of cardiovascular and kidney complications, and in the majority of ...